Combivir

HIV, Treatment Naive, HIV + 3 more
Treatment
3 FDA approvals
20 Active Studies for Combivir

What is Combivir

LamivudineThe Generic name of this drug
Treatment SummaryDideoxycytidine is a medication used to treat HIV-1 and hepatitis B. It works by inhibiting a reverse transcriptase enzyme that is found in the viruses. Dideoxycytidine is similar to the drug zalcitabine, but it has an extra sulfur atom in its pentose ring.
Epiviris the brand name
image of different drug pills on a surface
Combivir Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Epivir
Lamivudine
1995
178

Approved as Treatment by the FDA

Lamivudine, otherwise called Epivir, is approved by the FDA for 3 uses which include HIV and Chronic Hepatitis B Infection .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir
Chronic Hepatitis B Infection
HIV

Effectiveness

How Combivir Affects PatientsLamivudine is a medication that interferes with the replication of HIV-1 and hepatitis B. When it is changed by the body, it forms active components that try to attach to the virus' DNA. This stops the virus from reproducing and stops it from spreading further. Lamivudine also prevents the virus from forming new DNA strands, which it needs to survive.
How Combivir works in the bodyLamivudine works by preventing HIV and HBV from making copies of themselves. It does this by entering the cell and attaching itself to the virus' DNA. This stops the virus from replicating, which effectively stops it from spreading.

When to interrupt dosage

The proposed dose of Combivir is contingent upon the diagnosed condition. The quantity likewise changes as indicated by the technique of delivery laid out in the table beneath.
Condition
Dosage
Administration
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
Treatment Naive
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
Anti-Retroviral Agents
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
Chronic Hepatitis B Infection
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
treatment failure
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Combivir.
Common Combivir Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Combivir Toxicity & Overdose RiskCommon side effects of this drug in adults include headache, nausea, feeling unwell, nasal discomfort, diarrhea, and coughing.
image of a doctor in a lab doing drug, clinical research

Combivir Novel Uses: Which Conditions Have a Clinical Trial Featuring Combivir?

Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Chronic Hepatitis B Infection
8 Actively Recruiting
Phase 3, Phase 2, Phase 1
Treatment Naive
0 Actively Recruiting
treatment failure
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting

Combivir Reviews: What are patients saying about Combivir?

5Patient Review
10/28/2008
Combivir for HIV
This treatment is truly life-changing. It has helped me manage my HIV effectively and I couldn't be more grateful.
5Patient Review
9/20/2008
Combivir for HIV
I've been on Combivir for 12 years now with no ill effects that I'm aware of. Reyataz, however, raised my liver enzymes in 3 different categories to over 325. This could have easily destroyed my liver had I not caught it in time. If you're prescribed this drug, make sure to get a follow-up blood draw a few weeks later just to be safe. It's important to be proactive when it comes to your health!
5Patient Review
11/20/2007
Combivir for HIV
5Patient Review
1/21/2008
Combivir for HIV
4.3Patient Review
2/23/2014
Combivir for HIV
The AZT component of this treatment can be tiring. I've learned to live with the chronic fatigue, but it still frustrates me.
4Patient Review
1/14/2012
Combivir for HIV
I got really sick to my stomach from this treatment, and I had chills and cramps.
4Patient Review
8/6/2009
Combivir for HIV
I've been living with HIV for 13 years and have an undetectable viral load and over 1,000 T-cells. I take Trizivir every morning and night without fail.
4Patient Review
1/5/2009
Combivir for HIV
This drug has been keeping me alive for the past 10 years and I have had no negative side effects from it.
3.3Patient Review
9/20/2015
Combivir for HIV
I took this for a few years and then had to get 35 blood transfusions because I stopped producing it.
3Patient Review
3/14/2008
Combivir for HIV
I've been taking Combivir for five years and have had no negative experiences.
2.3Patient Review
10/3/2010
Combivir for Prevention of HIV Infection after Exposure
I've been on this medication for five years with no issues, but my doctor wants to take me off of it because of the potential side effect of lipodistrophy. I don't know if switching medications is worth the risk.
1.7Patient Review
1/17/2014
Combivir for Prevention of HIV Infection after Exposure
I was prescribed the "protocol" antivirals after being stuck by a needle. The patient I got it from was hep c+ and known iv drug user, and the medications made me sick to my stomach after one dose.I was advised that I did not have to take anymore, several days later, all of my muscles, joints, were so sore, I cold barely lift my arms above shoulders, and walking was painful. Not sure if my "employee health" advisors take this seriously>
1.3Patient Review
7/6/2013
Combivir for Prevention of HIV Infection after Exposure
Since I started this medication, I have felt really terrible. It's like moving through molasses and my thinking is very foggy. I'm exhausted all the time. Has anyone else experienced anything similar?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about combivir

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How effective is Combivir?

"Combivir is a highly effective antiretroviral drug when used in conjunction with other antiretroviral medications. The efficacy of the drug stems from its ability to lower the amount of the virus in the body, as well as prevent the virus from mutating and becoming resistant to the medication."

Answered by AI

Is Combivir still used?

"All people living with HIV are approved to use Combivir, which is a combination of two drugs: Retrovir and Epivir. Both drugs can still be bought seperately to use with other HIV drugs."

Answered by AI

What is Combivir tablets used for?

"The drug Combivir is indicated for use in combination with other antiretroviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection. It is recommended that only physicians experienced in the management of HIV infection prescribe this drug. Combivir may be taken with or without food."

Answered by AI

What type of drug is Combivir?

"Combivir is a medication used to treat HIV. It is a combination of two drugs, AZT and 3TC, which are both nucleoside analogues. These drugs work by stopping the HIV virus from replicating. Combivir is usually used in combination with other antiretroviral drugs."

Answered by AI

Clinical Trials for Combivir

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Combivir clinical trials? We made a collection of clinical trials featuring Combivir, we think they might fit your search criteria.Go to Trials
Have you considered Combivir clinical trials? We made a collection of clinical trials featuring Combivir, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Combivir clinical trials? We made a collection of clinical trials featuring Combivir, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security